Shenzhen Cell Valley successfully completed Angel +Pre-A round of capital increase
Recently, our company successfully completed the Angel +Pre-A round of capital increase and share expansion of nearly 100 million yuan, which injected strong impetus into the future development of Shenzhen Cell Valley. The capital increase and share expansion has been actively supported and recognized by new and old shareholders and investors, further enhancing the company's capital strength and market competitiveness.
The main purpose of the capital increase is to expand the company's business scale and improve the company's profitability and market competitiveness. Through the capital increase and share expansion, the company successfully introduced new investors, further optimized the company's ownership structure, and laid a solid foundation for the company's long-term development.
Uphold the concept and forge ahead
In the recent capital winter dilemma, especially in the global cell and gene industry is facing adjustment and comprehensive reshuffle, Cell Valley people adhering to the concept of "cells benefit all beings, genes create the future", down-to-earth, deep digging the market, adhere to the "research and development of new technology, forge new production, create new formats, open up new markets", adhere to building a technology-driven modern enterprise. Through the unremitting efforts of all employees, Shenzhen Cell Valley has overcome a number of domestic and international technical problems in cell therapy, such as the production and quality control technology of allogeneic NK cells, the successful development of a new virus vector virus-producing engineering cell line with its own intellectual property rights, and the international leading reverse-virus vector stock liquid transduction efficiency of primary NK cells exceeding 90%. The company also experienced rapid revenue growth in the first quarter, and carried out a number of clinical research collaborations with top public hospitals in China, including Cancer Hospital of Chinese Academy of Medical Sciences, Beijing Children's Hospital, and Cancer Prevention and Control Center of Sun Yat-sen University.
The success of the capital increase and share expansion not only highlights the strong attraction and market potential of Shenzhen Cell Valley, but also reflects the confidence and recognition of shareholders and investors in the company. In the future, Shenzhen Cell Valley will continue to uphold the innovative, pragmatic and prudent business philosophy, and constantly promote the company's business expansion and transformation and upgrading, to create more lucrative returns for shareholders and investors.
We believe that with the joint support of our shareholders and investors,
Shenzhen Cell Valley will usher in a more brilliant future!
